Collaboration deepens strategic partnership between two Indian-Chinese companies Ahmedabad-headquartered Intas Pharmaceuticals Limited has entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the development and commercialisation of serplulimab for the European and Indian markets. Serplulimab, a...
Read moreDetails









